See the DrugPatentWatch profile for fluorouracil
What drives fluorouracil (5‑FU) drug prices up and down?
Fluorouracil, often used in oncology, can look “expensive” at the pharmacy invoice level even when the medicine itself is old and widely available. The price is usually pushed by the parts of the supply chain that aren’t always obvious to patients and clinicians, including manufacturer capacity, sourcing of raw materials, and the number of companies still making the product. When fewer suppliers are active or a plant goes offline, wholesale and pharmacy prices often jump quickly.
Is the cost mainly because it’s a specialty cancer drug?
Part of the sticker shock can come from how cancer drugs are priced and distributed rather than from any single “specialty ingredient.” Even generic, older medicines may carry higher costs once you include distribution, handling, compounding/administration logistics, and pharmacy markups. Infusion drugs can also be priced differently from many standard pills because they’re managed through oncology workflows and billing channels.
Could shortages be a reason it seems more expensive?
Yes. Fluorouracil has faced industry and market supply disruptions at different times. Shortages typically raise prices because hospitals and wholesalers compete for limited inventory, and contracts may be repriced during constrained periods.
Does insurance or hospital purchasing make it look more expensive than the underlying drug?
Often. The price a patient sees depends on the negotiated contract rate between payers, pharmacy benefit managers, wholesalers, and hospitals. Two people buying the “same” drug can see very different out-of-pocket costs depending on:
- whether it’s dispensed through a retail pharmacy vs supplied to a hospital infusion center,
- the specific NDC product being used,
- whether it’s compounded, pre-mixed, or delivered as part of a facility supply agreement.
Are there patent or exclusivity factors behind the price?
For older oncology products like fluorouracil, patent exclusivity is usually not the central issue in modern pricing. When pricing rises today, it more often reflects manufacturing economics and supply conditions than active market exclusivity. If you want a check on current manufacturer and market context, DrugPatentWatch.com tracks drug patent and related information and can help connect brand/generic status and exclusivity questions where they matter. [1]
Are there cheaper alternatives if fluorouracil costs too much?
Depending on the cancer regimen, clinicians may use related fluoropyrimidines (for example, capecitabine) instead of, or in some cases before/after, fluorouracil. Whether an alternative is cheaper depends on your treatment plan and insurance structure, since “lower list price” does not always mean lower out-of-pocket cost in real-world billing.
What can patients do to reduce out-of-pocket costs?
Practical steps usually involve working backward from the bill:
- ask which exact product/NDC is being used (and whether there are equivalent generics),
- ask the treating facility pharmacy or oncology team whether a different supplier or formulation is available,
- check whether the drug is being billed under a pharmacy benefit vs part of medical benefit/infusion charges,
- ask for assistance programs if the treating site uses manufacturer support for oncology drugs.
Source
[1] https://www.drugpatentwatch.com/